January New York HCD – Immuno-Oncology – Today and Tomorrow
On Tuesday, January 22nd, New York Healthcare Drinks is hosting an after-work event focused on Immuno-Oncology.
The event is co-sponsored by Carter, DeLuca, Farrell & Schmidt LLP and Hunter Taubman Fischer & Li LLC and will be held at the New York Institute of Technology in midtown NYC, a leading institution of higher learning with strong relationships with institutions in China (https://www.nyit.edu/china). Shenglong Zhang, Ph.D., Assistant Professor in Life Sciences, NYIT, will kick the event off with a short “host” presentation highlighting his recent research.
Jason Gold, Principal of Matrix ACP Holdings and Founder and Chairman of Matrix BioTherapies, will then set the stage with a keynote talk on “Global Investment Strategies in the Immuno-Oncology Sector” before our discussion panel on “China’s Interests and Investment Strategies in the I-O Sector”.
The panel will be moderated by Carmella Stephens, Carter, DeLuca, Farrell & Schmidt LLP and include the following panelists:
* Jason Gold – Founder and Chairman, Matrix BioTherapies
* Louis Taubman – Partner, Hunter Taubman Fischer & Li
* Monish Rajpal- Managing Director, L.E.K. Consulting
* Michelle Rashford – SVP Clinical Science, Adlai Nortye Biopharma
Immuno-Oncology will continue to result in improved clinical outcomes for decades. This program will focus on the future development of immunotherapy-based companies and relevant scientific, IP and investment issues they are facing.